Kane Biotech Inc. (KNE.V)
- GlobeNewswire
Kane Biotech Receives an Additional $425K USD of Funding for its DispersinB® Hydrogel from the United States Department of Defense
DispersinB® Hydrogel Clinical trials to commence in 2022WINNIPEG, Manitoba, Oct. 04, 2022 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”) today announces that it has received an additional $425,000 USD of funding for its DispersinB Hydrogel® related to its Medical Technology Enterprise Consortium Research Project Award which was granted in 2020 and funded by the U.S. Department of Defense. This additional funding supplements the approximately $2.7
- GlobeNewswire
Kane Biotech Announces Second Quarter 2022 Financial Results
Significant Milestones AchievedWINNIPEG, Manitoba, Aug. 25, 2022 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”) today announced its second quarter 2022 financial results. Second Quarter Financial Highlights: Total revenue for the three months ended June 30, 2022 was $839,579, an increase of 201% compared to $278,741 in the three months ended June 30, 2021.License revenue in the three months ended June 30, 2022 was $500,225, an increase of 1,295%
- GlobeNewswire
Kane Biotech to Release Second Quarter 2022 Financial Results on August 25, 2022 – Conference Call to Follow
WINNIPEG, Manitoba, Aug. 18, 2022 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”), a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms, will announce its second quarter 2022 financial results after market close on Thursday, August 25, 2022. Kane Biotech management will host a conference call at 4:30 p.m. ET to review the financial results and di
